Severe Weight Loss During PD-1 Treatment is a Risk Sign of Poor Prognosis for Advanced GC Patients

Overview

Journal Int J Clin Oncol

Specialty Oncology

Date 2024 Jul 30

PMID 39080116

Authors

Jun Geng

Ruming Liu

Lin Zhang

Longbo Gong

Liang Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: To verify whether severe weight loss is a reasonable risk sign for the effect of PD-1 treatment in advanced gastric cancer (GC) patients.

Methods: 127 metastatic or recurrent GC patients treated with PD-1 inhibitors in Xuzhou Central Hospital were involved in this study. Two cohorts with different variables were built; one was used to reveal the relationship between body weight loss and overall survival (OS), and the other was used to find which body composition contributed to the weight loss. Variables were collected at PD-1 inhibitor initiation (baseline) and week 6 of treatment. Patients were followed up from the end of therapy to November 2022. Overall survival (OS) and disease-free survival (DFS) were recorded.

Results: 127 patients with metastatic/recurrent gastric cancer received PD-1 treatment, among whom 117 had complete weight data. After screening, data from 69 patients were used for body composition assessment. The study found that 33 patients who lost more than 2% of their body weight within six weeks had poorer OS and DFS, with medians of 9.5 months and 6 months, respectively. Cox regression analysis showed that weight loss of more than 2% and treatment methods was an independent risk for poor OS and DFS. Further analysis revealed that weight loss was mainly caused by a reduction in adipose tissue, rather than muscle mass.

Conclusion: Severe weight loss is a potential monitor for the treatment effect of PD-1 inhibitor in advanced GC patients.

References

Argiles J, Stemmler B, Lopez-Soriano F, Busquets S . Inter-tissue communication in cancer cachexia. Nat Rev Endocrinol. 2018; 15(1):9-20. DOI: 10.1038/s41574-018-0123-0. View

Chung K, Nati M, Chavakis T, Chatzigeorgiou A . Innate immune cells in the adipose tissue. Rev Endocr Metab Disord. 2018; 19(4):283-292. DOI: 10.1007/s11154-018-9451-6. View

Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F . A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer. 2019; 7(1):57. PMC: 6391761. DOI: 10.1186/s40425-019-0527-y. View

Degens J, Dingemans A, Willemsen A, Gietema H, Hurkmans D, Aerts J . The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab. J Cachexia Sarcopenia Muscle. 2021; 12(3):657-664. PMC: 8200425. DOI: 10.1002/jcsm.12698. View

Fearon K, Strasser F, Anker S, Bosaeus I, Bruera E, Fainsinger R . Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12(5):489-95. DOI: 10.1016/S1470-2045(10)70218-7. View

Feng X, Wang L, Zhou R, Zhou R, Chen L, Peng H . Senescent immune cells accumulation promotes brown adipose tissue dysfunction during aging. Nat Commun. 2023; 14(1):3208. PMC: 10237528. DOI: 10.1038/s41467-023-38842-6. View

Formica V, Morelli C, Patrikidou A, Shiu K, Nardecchia A, Lucchetti J . A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma. Crit Rev Oncol Hematol. 2020; 157:103173. DOI: 10.1016/j.critrevonc.2020.103173. View

Han J, Tang M, Lu C, Shen L, She J, Wu G . Subcutaneous, but not visceral, adipose tissue as a marker for prognosis in gastric cancer patients with cachexia. Clin Nutr. 2021; 40(9):5156-5161. DOI: 10.1016/j.clnu.2021.08.003. View

He M, Chen Z, Zhang L, Gao X, Chong X, Li H . Associations of subcutaneous fat area and Systemic Immune-inflammation Index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade. J Immunother Cancer. 2023; 11(6). PMC: 10314655. DOI: 10.1136/jitc-2023-007054. View

10.

Kichenadasse G, Miners J, Mangoni A, Rowland A, Hopkins A, Sorich M . Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2019; 6(4):512-518. PMC: 6990855. DOI: 10.1001/jamaoncol.2019.5241. View

11.

Kubo Y, Miyata H, Sugimura K, Shinno N, Asukai K, Hasegawa S . Prognostic Implication of Postoperative Weight Loss After Esophagectomy for Esophageal Squamous Cell Cancer. Ann Surg Oncol. 2020; 28(1):184-193. DOI: 10.1245/s10434-020-08762-6. View

12.

Matsui R, Inaki N, Tsuji T . Impact of visceral adipose tissue on compliance of adjuvant chemotherapy and relapse-free survival after gastrectomy for gastric cancer: A propensity score matching analysis. Clin Nutr. 2021; 40(5):2745-2753. DOI: 10.1016/j.clnu.2021.04.019. View

13.

Miyawaki T, Naito T, Yabe M, Kodama H, Nishioka N, Miyawaki E . Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer. Support Care Cancer. 2021; 30(2):1633-1641. DOI: 10.1007/s00520-021-06572-4. View

14.

Mourtzakis M, Prado C, Lieffers J, Reiman T, McCargar L, Baracos V . A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008; 33(5):997-1006. DOI: 10.1139/H08-075. View

15.

Nikniaz Z, Somi M, Naghashi S . Malnutrition and Weight Loss as Prognostic Factors in the Survival of Patients with Gastric Cancer. Nutr Cancer. 2022; 74(9):3140-3145. DOI: 10.1080/01635581.2022.2059089. View

16.

Prado C, Lieffers J, McCargar L, Reiman T, Sawyer M, Martin L . Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008; 9(7):629-35. DOI: 10.1016/S1470-2045(08)70153-0. View

17.

Roeland E, Bohlke K, Baracos V, Bruera E, Del Fabbro E, Dixon S . Management of Cancer Cachexia: ASCO Guideline. J Clin Oncol. 2020; 38(21):2438-2453. DOI: 10.1200/JCO.20.00611. View

18.

Rounis K, Makrakis D, Gioulbasanis I, Ekman S, De Petris L, Mavroudis D . Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies. Life (Basel). 2022; 12(6). PMC: 9225288. DOI: 10.3390/life12060880. View

19.

Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge M, Albu J . Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 2004; 97(6):2333-8. DOI: 10.1152/japplphysiol.00744.2004. View

20.

Wang Z, Aguilar E, Luna J, Dunai C, Khuat L, Le C . Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2018; 25(1):141-151. PMC: 6324991. DOI: 10.1038/s41591-018-0221-5. View